Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

1. Gene by environment interaction effects on the metabolic subtype of Polycystic Ovary Syndrome in Hispanic Community Health Study/Study of Latinos.Frontiers in genetics · 2026
   Article
2. The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025
   Review
3. Mechanisms of Polycomb group protein function in cancer.Cell research · 2022
   Review
4. Epigenetic Regulation of Intestinal Stem Cells and Disease: A Balancing Act of DNA and Histone Methylation.Gastroenterology · 2021
   Review
5. Chromatin Regulator SPEN/SHARP in X Inactivation and Disease.Cancers · 2021
   Review
6. Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies.International journal of molecular sciences · 2020
   Review
7. EZH2 in Myeloid Malignancies.Cells · 2020
   Review
8. Towards understanding of PRC2 binding to RNA.RNA biology · 2019
   Review
9. Structures of human PRC2 with its cofactors AEBP2 and JARID2.Science (New York, N.Y.) · 2018
   Article
10. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies.Experimental hematology · 2017
    Review
11. H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.Advances in cancer research · 2016
    Review
12. Somatic alterations and dysregulation of epigenetic modifiers in cancers.Biochemical and biophysical research communications · 2014
    Review
13. Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors.Nature genetics · 2014
    Article
14. Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014
    Review
15. Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms.Leukemia · 2014
    Article
16. Array comparative genomic hybridization and sequencing of 23 genes in 80 patients with myelofibrosis at chronic or acute phase.Haematologica · 2014
    Article
17. Genomics of lymphoid malignancies reveal major activation pathways in lymphocytes.Journal of autoimmunity · 2013
    Review
18. Epigenetic alterations in hematopoietic malignancies.International journal of hematology · 2012
    Review
19. The role of mutations in epigenetic regulators in myeloid malignancies.Nature reviews. Cancer · 2012
    Review
20. Alterations of polycomb gene BMI1 in human myeloproliferative neoplasms.Cell cycle (Georgetown, Tex.) · 2012
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

11 authors at 4 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.